INS and metabolic syndrome: The absence of differences in fibroblast growth factor in the main and control groups is explained by the multifocal property of this metabolic regulator in middle-aged and elderly people; its increase is probably associated with a compensatory decrease in insulin resistance, as well as correction of dyslipidemia due to activation of lipolysis, b-oxidation in the liver [28].